Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Nonalcoholic Steatohepatitis: Epidemiology, Screening, Risk Assessment, Diagnosis, and Management

Quentin M. Anstee, BSc, MB BS, PhD, MRCP(UK), FRCP
Program Director
Philip N. Newsome, PhD, FRCPE
Released: August 21, 2019

Primary Care Essentials

The first aim for a primary care provider is to identify which patients with NAFLD have advanced liver fibrosis and refer further workup and management to specialists. Most patients with NAFLD do not have advanced liver fibrosis or disease and many will not progress to NASH. For patients with NAFLD and no significant fibrosis, the primary care provider plays a critical role in the holistic management of the metabolic syndrome to mitigate cardiovascular, metabolic, and other nonliver pathology. For those patients with nonalcoholic steatohepatitis, specialist care will be important for the introduction of therapies as they are approvedIt is likely that some of these therapies will transfer to primary care over time whereas more involved therapies, such as induction antifibrotics, will continue to be administered by specialists.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings